Prime shows how carve-in wins for clients—it’s better than carve-out.

June 1, 2020

For the first time, Prime’s puts its carve-in analytics through a rigorous scientific peer review. It’s clear.  This published, peer reviewed study showed  Regence and Prime carve-in pharmacy was associated with lowered overall health care costs.

Carve-out is out. This study used medical data and followed members for two years. The final cohorts consisted of 205,835 carve-in and 125,555 carve-out members.

Compared to the carve out members, members with carve-in benefits had an average:

  • $148 lower total medical cost PMPY 
  • 15% lower odds of hospitalization 
  • 7% lower odds of ED visit

In 5 of 7 chronic conditions, members with carve-in benefits had significant lower costs and medical event odds as shown here: 

  • 12%-17% lower medical costs
  • 22%-36% lower odds of hospitalization 
  • 16%-20% lower odds of ED visit 

The study findings indicate that integrated, carve-in pharmacy and medical benefits are associated with lower medical costs, fewer hospitalizations, and fewer ED visits.

This study, co-authored by researchers at Prime and Regence Health Plans, is to our knowledge, the only scientifically peer-reviewed study published on the subject. The authors received a platinum award for this research, which is published in the peer-reviewed Journal of Managed Care & Specialty Pharmacy (JMCP).

Medical Costs and Health Care Utilization Among Self-Insured Members with Carve-In Versus Carve-Out Pharmacy Benefits (Spring 2020)

Related news

Perspectives

April 17, 2024

AMCP 2024: Behind the research with YuQian Liu

Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier

Perspectives

April 16, 2024

AMCP 2024: Behind the research with Jacob LaRue and Timothy O’Shea

Ahead of their session, Jacob and Timothy share how Prime/MRx is working alongside providers like Horizon Blue Cross Blue Shield of New Jersey to manage drug waste and rein in spend for specialty drugs without therapeutic impact to patients

Perspectives

April 15, 2024

Oncology Insights: Cancer treatment is personal

Precision medicine, or personalized medicine, uses genes or proteins to diagnose or treat disease. This medical care design has significantly impacted oncology and grew out of a need to improve and individualize patient treatments